ellume Logo
Menu
NewsCareersContact
Privacy PolicyTerms & Conditions
HomeFor Professionals

For Professionals

ellume·lab provides rapid diagnostic tests and clinical decision-making tools for healthcare professionals at the point-of-care. To protect frontline healthcare workers, our swab+drop Self-Swab Kit enables self-collection and laboratory analysis.

Doctor holding ellume·lab on home screen
The ellume lab device
ellume lab logo

The ellume·lab is designed to assist primary healthcare professionals at the point-of-care. ellume·lab offers a growing range of highly accurate, rapid diagnostic tests for the detection of common infectious diseases.

ellume·lab provides practitioners with a suite of digital tools to support clinical decision-making and enhance patient engagement, on the same device. All ellume·lab digital tools offer secure, HIPAA compliant cloud connectivity for sharing results with patients or other healthcare professionals.

Available in U.S. only.

Learn more
The QuantiFeron testing hub

QIAreach™

In partnership with QIAGEN®, Ellume has accelerated the development of two rapid, reliable COVID-19 tests to support the global response to the coronavirus pandemic.

The QIAreach™Anti-SARS-CoV-2 Total Test, is a high-performance serological test which detects antibodies in people who have been exposed to SARS-CoV-2. The test received U.S. FDA Emergency Use Authorization (EUA) in May 2021**.

The QIAreach™ Anti-SARS-CoV-2 Antigen Test detects SARS-CoV-2 antigens in people with active infections. The test received U.S. FDA Emergency Use Authorization (EUA) in August 2021***.

Learn more
The ellume lab device
ellume lab logo

The ellume·lab is designed to assist primary healthcare professionals at the point-of-care. ellume·lab offers a growing range of highly accurate, rapid diagnostic tests for the detection of common infectious diseases.

ellume·lab provides practitioners with a suite of digital tools to support clinical decision-making and enhance patient engagement, on the same device. All ellume·lab digital tools offer secure, HIPAA compliant cloud connectivity for sharing results with patients or other healthcare professionals.

Available in U.S. only.

Learn more
The QuantiFeron testing hub

QIAreach™

In partnership with QIAGEN®, Ellume has accelerated the development of two rapid, reliable COVID-19 tests to support the global response to the coronavirus pandemic.

The QIAreach™Anti-SARS-CoV-2 Total Test, is a high-performance serological test which detects antibodies in people who have been exposed to SARS-CoV-2. The test received U.S. FDA Emergency Use Authorization (EUA) in May 2021**.

The QIAreach™ Anti-SARS-CoV-2 Antigen Test detects SARS-CoV-2 antigens in people with active infections. The test received U.S. FDA Emergency Use Authorization (EUA) in August 2021***.

Learn more
The ellume lab device
ellume lab logo

The ellume·lab is designed to assist primary healthcare professionals at the point-of-care. ellume·lab offers a growing range of highly accurate, rapid diagnostic tests for the detection of common infectious diseases.

ellume·lab provides practitioners with a suite of digital tools to support clinical decision-making and enhance patient engagement, on the same device. All ellume·lab digital tools offer secure, HIPAA compliant cloud connectivity for sharing results with patients or other healthcare professionals.

Available in U.S. only.

Learn more
The QuantiFeron testing hub

QIAreach™

In partnership with QIAGEN®, Ellume has accelerated the development of two rapid, reliable COVID-19 tests to support the global response to the coronavirus pandemic.

The QIAreach™Anti-SARS-CoV-2 Total Test, is a high-performance serological test which detects antibodies in people who have been exposed to SARS-CoV-2. The test received U.S. FDA Emergency Use Authorization (EUA) in May 2021**.

The QIAreach™ Anti-SARS-CoV-2 Antigen Test detects SARS-CoV-2 antigens in people with active infections. The test received U.S. FDA Emergency Use Authorization (EUA) in August 2021***.

Learn more
*The ellume·lab product has not been FDA cleared or approved, but has been authorized by the FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. **QIAreach™ Anti-SARS-CoV-2 Total testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C §263a, that meet requirements to perform moderate or high complexity tests. This test has not been FDA cleared or approved but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; this test has been authorized only for detecting the presence of total antibodies to SARS-CoV-2, not for any other viruses or pathogens; and the emergency use of this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities. ***QIAreach™ Anti-SARS-CoV-2 Antigen Test has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
We use cookies
Ellume Limited values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Others are optional: performance cookies show us how you use our website and features; functional cookies remember your preferences; and advertising cookies help us share relevant content. Cookies Policy.